Sign in Subscribe
Health care industry

Evogenix Ltd Debut on Australian Stock Exchange Amid Challenging Biotech Market

Strategic Insights

— 1 min read

Freshly-listed biotech company Evogenix Ltd (ASX:EGX) has made a debut on the Australian Stock Exchange, despite the challenging biotech market. The company's shares floated at 30 cents, a 5 cent premium to the 25 cent issue price, but closed at 27.5 cents. Evogenix's focus on early revenues and three antibody products sets it apart from other biotech stocks. The $A9 million float will be used to accelerate the development of these products, which target diseases such as osteoporosis, liver cancer, and respiratory disease.

Key Takeaways:

  • Evogenix Ltd (ASX:EGX) debuted on the Australian Stock Exchange with a share price of 30 cents, a 5 cent premium to the 25 cent issue price.
  • The company's focus on early revenues and development of three antibody products differentiates it from other biotech stocks.
  • The $A9 million float will be used to accelerate the development of these products, which target diseases such as osteoporosis, liver cancer, and respiratory disease.
  • Evogenix was formed four years ago to develop science coming out of the Cooperative Research Centre for Diagnostics and CSIRO Division of Health Sciences and Nutrition.
  • The company has merged with California-based Abalus Inc, a fellow therapeutic antibody company, to put together a set of key technologies.
  • Evogenix's first product, targeting osteoporosis, is expected to be ready for licensing to a large pharmaceutical company next year.
  • Pharmaceuticals are turning to the antibody market for new products as patent expirations and shareholder pressure increase.

Statistics:

  • The initial public offer (IPO) of Evogenix closed early last month, with strong support from both institutional and retail investors.
  • The $A9 million float as part of the IPO.
  • Evogenix shares closed at 27.5 cents, a decrease from the debut price of 30 cents.

Sources:

  • "Evogenix Ltd Debut on Australian Stock Exchange Amid Challenging Biotech Market". Asia Pulse. 15 Aug 1922. (Source: Asia Pulse)

Read more